Two cases of skin hyperpigmentation induced by polymyxin B

Main Article Content

Cássio Alexandre Oliveira Rodrigues
Rand Randall Martins
Eduardo Queiroz da Cunha
Marizaldo de Souto Lima
Valdjane Saldanha


Introduction: The skin hyperpigmentation process involves biochemical and immunological mechanisms that stimulate melanogenesis and although nephrotoxicity consists of the most relevant adverse reaction of polymyxin B, it is also associated with this changes. Case report: Case 1: male patient, diagnosed with Hodgkin’s Lymphoma, who developed skin hyperpigmentation after starting treatment with meropenem, anidulafungin and polymyxin B due to a septic shock. Case 2: male patient, admitted to the ICU for decreased level of consciousness and suspected STEMI, diagnosed with endocarditis and pericarditis, who also presented skin hyperpigmentation during therapy with amphotericin B and polymyxin B. Conclusion: After careful evaluation of chronological order and drugs used by patients, we conclude that polymyxin B caused hyperpigmentation in both patients. Finally, based on the mechanism of this reaction and the scientific findings, clinical studies that may evidence a probable pharmacological effect with the use of H2 antagonists are required.


Download data is not yet available.

Article Details

How to Cite
Rodrigues, C. A. O., Martins, R. R., Cunha, E. Q. da, Lima, M. de S., & Saldanha, V. (2019). Two cases of skin hyperpigmentation induced by polymyxin B. ABCS Health Sciences, 44(2).


1. Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol. 2008;53(1):2-8.

2. Mattos KPH, Cintra ML, Gouvêa IR, Ferreira LA, Velho PENF, Moriel P. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process. J Clin Pharm Ther. 2017;42(5):573-8.

3. Mendes CAC, Burdmann EA. Polimixinas: revisão com ênfase na sua nefrotoxicidade. Rev Assoc Med Bras. 2009; 55(6):752-9.

4. Knueppel RC, Rahimian J. Diffuse cutaneous hyperpigmentation due to tygecicline or polymyxyn B. Clin Infect Dis. 2007;45(1):136-8.

5. Mattos KPH, Lloret GR, Cintra ML, Gouvêa IR, Betoni RT, Mazzola PG, et al. Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study. Pigment Cell Melanoma Res. 2016;29(3):388-90.

6. Gothwal S, Meena K, Sharma SD. Polymyxyn B induced generalized hyperpigmentation in neonates. Indian J Pediatr. 2016;83(2):179-80.

7. Zavascki AP, Manfro RC, Maciel RA, Falci DR. Head and neck hyperpigmentation probably associated with polymyxin B therapy. Ann Pharmacother. 2015;49(10):1171-2.

8. Lahiry S, Choudhury S, Mukherjee A, Bhunya PK, Bala M. Polymyxin B-induced diffuse cutaneous hyperpigmentation. J Clin Diagn Res. 2017;11(2):FD01-2.

9. Zavascki AP, Schuster LF, Duquia RP. Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation. Int J Antimicrob Agents. 2016;48(5):579-80.

10. Torres V, Herane MI, Costa A, Martin JP, Troielli P. Refinando as ideias sobre a pele "étnica". An Bras Dermatol. 2017;92(2):221-5.

11. Bushby SRM, Green AF. The release of histamine by polymyxin B and polymyxin E. Br J Pharmacol. 1955;10(2):215-9.

12. Yoshida M, Takahashi Y, Inoue S. Histamine induces melanogenesis and morphologic changes by protein kinase A activation via H2 receptors in human normal melanocytes. J Investig Dermatol. 2000;114(2):334-42.

13. Yoshida M, Hirotsu S, Nakahara M, Uchiwa H, Yasushi T. Histamine is envolved in ultravioleta B-induced pigmentation of guinea pig skin. J Investig Dermatol. 2002;118(2):255-60.

14. Thomas RH, Browne PD, Kirby JD. The influence of ranitidine, alone and in combination with clemastine, on histamine-mediated cutaneous weal and flare reactions in human skin. Br J Clin Pharmacol. 1985;20(4):377-82.